BiotechTube
Biogenes

Biogenes

Berlin, Germany· Est.
biogenes.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

BioGenes is a well-established, privately-held service provider based in Berlin, Germany, with a strong reputation in the biopharma outsourcing sector. The company generates revenue by offering custom antibody generation, ELISA kit development, and specialized analytical services, with a particular focus on HCP impurity monitoring for drug developers. With an ISO 9001:2015 certified quality system and a long list of blue-chip pharmaceutical and biotech clients, BioGenes has built a sustainable business model on technical excellence, reliability, and deep customer relationships. Its outlook is positive, supported by the growing global biopharmaceutical pipeline and increasing regulatory emphasis on impurity characterization.

Antibodies

Technology Platform

Integrated suite of immunological and bioanalytical capabilities for custom antibody development (from antigen design to production), specialized Host Cell Protein (HCP) immunoassay development, and complex analytical service provision for biopharmaceutical quality control.

Funding History

1
Total raised:$2M
Seed$2M

Opportunities

The growing global pipeline of biologic drugs and biosimilars drives sustained demand for specialized development and analytical services.
Increasing regulatory focus on impurity characterization, particularly for high-risk Host Cell Proteins (HCPs), creates a strong niche for their advanced ELISA kits.
The trend towards outsourcing by biopharma companies presents a continued tailwind for their contract service model.

Risk Factors

Revenue is tied to the R&D spending cycles of the biopharmaceutical industry, which can be volatile.
The company faces intense competition from both large global CROs and niche specialists.
Technological disruption from alternative analytical methods (e.g., mass spectrometry) could challenge some of their core service offerings.

Competitive Landscape

BioGenes competes in the fragmented contract research and service organization (CRO/CSO) market. It differentiates itself through deep specialization in custom antibodies and HCP analytics, competing against larger, less specialized players like Charles River or Labcorp on expertise and flexibility, and against smaller niche labs on scale, reputation, and a full-service offering. Its 30-year track record and ISO certification are key competitive assets.

More companies in Biologics / Biosimilars →More companies in Germany →